A first-in-class mAb, directed against a key immune checkpoint, PVR (CD155). NTX1088 demonstrated superior antitumor activity compared to approved and investigational Immune Checkpoint Inhibitors (ICIs) in pre-clinical models. NTX1088 has a favorable safety profile in non-human primates (NHP). An ongoing phase 1 clinical trial is evaluating NXT1088 as a mono-therapy and in combination with KEYTRUDA® (pembrolizumab).
This project is co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.
Nectin Therapeutics is engaged in the development of a pipeline of first-in-class and best-in-class ADC therapies. Our candidates have demonstrated robust tumor regression in multiple in vivo models of solid and hematological malignancies. Our ADC programs are currently undergoing IND-enabling studies.
NTX3A13 a first-in-class multispecific therapeutic antibody is engineered to simultaneously recognize and bind to several undisclosed antigens, including a key member of the nectin pathway. By integrating multiple, high-affinity binding domains within a single molecule, this agent is designed to selectively target cancer cells with increased precision, disrupt critical signaling networks involved in tumor growth and immune evasion. NTX3A13 is currently in the lead-selection stage.